GE HealthCare Technologies Inc. (GEHC)
(Delayed Data from NSDQ)
$85.09 USD
-2.20 (-2.52%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $84.75 -0.34 (-0.40%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
GEHC 85.09 -2.20(-2.52%)
Will GEHC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GEHC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GEHC
Can Cloud Momentum Drive Amazon's Stock Beyond Its 14.1% YTD Gain?
GE Healthcare to Unveil AI-Driven Cardiac Diagnostics at ESC 2024
GEHC: What are Zacks experts saying now?
Zacks Private Portfolio Services
GE HealthCare's (GEHC) Tie-Up to Boost Female Pelvic Healthcare
Why GE HealthCare Technologies (GEHC) is a Top Value Stock for the Long-Term
Why GE HealthCare Technologies (GEHC) is a Top Value Stock for the Long-Term
Other News for GEHC
Election 2024: Where To Put Your Money Ahead of the Vote
Perspective gets FDA fast track status for radiopharmaceutical VMT01
50 stocks to invest during the bull steepening – Part 1
Perspective gets FDA fast track status for radiopharmaceutical VMT101
Buy Rating Affirmed for GE HealthCare Technologies on Innovation and Strong Financial Outlook